Home Icon

Loading, Please Wait...

ImmusanT to Provide Corporate Overview at the Cowen & Company 39th Annual Health Care Conference

1171 Days ago

CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, today announced that Leslie Williams, Chief Executive Officer, will present a corporate overview at the Cowen & Company 39th Annual Healthcare Conference, taking place March 11-13 in Boston, Massachusetts.

Cowen 39th Annual Health Care Conference
Date: Monday, March 11
Time: 3:00pm Eastern Time
Webcast: http://wsw.com/webcast/cowen52/imst

About ImmusanT, Inc.
At ImmusanT, we are developing a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Our Epitope-Specific Immuno-Therapy™ (ESIT™) platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. Our lead program, Nexvax2®, is in clinical development with the goal of protecting celiac disease patients against the debilitating effects of gluten. www.ImmusanT.com 

Media Contact:
Andrew Mielach
Account Supervisor
LifeSci Public Relations
(646) 876-5868

We Are Diffrent
Is your business listed correctly on America’s largest city directory network of 1,000 portals? Find your City Portal